Clinical trial

An Open-Label, Staggered Rising Dose Cohort Study Assessing the…

NCT00000649 · Boehringer Ingelheim, Industry · Completed

Key facts

NCT number NCT00000649
Title An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3)
Official title An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3)
Lead sponsor Boehringer Ingelheim, Industry
Status Completed
Phase Phase 1
Study type Interventional
Conditions HIV Infections
Intervention type Drug
Interventions Nevirapine, Zidovudine
Enrollment 30
First posted Aug 31, 2001
Last update posted Jul 30, 2008
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies